Skip to main content
main-content

Neuer Inhalt Free Registration

Gain full access to the latest clinical content available from Springer Nature

Editors' pick

10-11-2017 | Rheumatoid arthritis | ACR/ARHP 2017 | News

Promising results with upadacitinib in RA patients

Results of the SELECT-BEYOND trial suggest that the Janus kinase inhibitor upadacitinib may be a useful treatment option for patients with treatment-refractory rheumatoid arthritis.

30-10-2017 | Gout | Themed collection | Collection

Urate-lowering therapies in gout

This content collection provides an overview of the pathogenesis of gout, followed by a review of current urate-lowering therapies, with an emphasis on their comparative safety and efficacy.

24-10-2017 | Rheumatoid arthritis | Editorial | Article

Demise of the triple

Editorial Board member Marc Cohen reviews the use of triple therapy for the treatment of rheumatoid arthritis, and discusses the possible reasons for its underutilization compared with biologic therapies.

Latest from across the site

22-11-2017 | Axial spondyloarthritis | News

Predictors of biologic treatment failure in AxSpA patients identified

 It may be possible to identify patients with axial spondyloarthritis who are unlikely to respond to tumor necrosis factor inhibitor treatment using their baseline factors, researchers report.

Source:

Arthritis Care Res 2017; Advance online publication

21-11-2017 | Juvenile idiopathic arthritis | ACR/ARHP 2017 | News

News in brief

Tocilizumab promising in short and long term for severe JIA-associated uveitis

The anti-interleukin-6 receptor antibody tocilizumab improves ocular outcomes in the short and long term in patients with severe uveitis related to juvenile idiopathic arthritis, indicates research presented at the 2017 ACR/ARHP Annual Meeting in San Diego, California, USA.

20-11-2017 | Osteoarthritis | ACR/ARHP 2017 | News

Sprifermin shows potential as a disease-modifying OA treatment

Results of the phase II FORWARD trial suggest that sprifermin, an investigational recombinant human fibroblast growth factor, may prevent cartilage loss in patients with knee osteoarthritis, but its effect on pain and physical function remains unclear.

20-11-2017 | Gout | News

Regulatory update

FDA announces febuxostat safety alert

Click through to read more on this announcement

17-11-2017 | Juvenile idiopathic arthritis | ACR/ARHP 2017 | News

Online self-management program boosts JIA HRQoL

An internet-based educational tool developed by Canadian researchers helps adolescents with juvenile idiopathic arthritis to manage their disease and leads to improvements in their health-related quality of life relative to standard disease education.

16-11-2017 | Rheumatoid arthritis | Conference report | News

Exploring RA treatment patterns

Several studies presented at the 2017 ACR/ARHP Annual Meeting in San Diego, California, USA, explored different aspects of rheumatoid arthritis treatment, including guideline recommendations, adherence to second-line therapy, and predicting treatment response.

Latest from us on Twitter

Meet our Editorial Board

image credits